- ►diabetesjournals.org E Bosi, RP Camisasca, C Collober, E … - Diabetes Care, 2007 - Am Diabetes Assoc RESULTS—The between-treatment difference (vildagliptin − placebo) in
adjusted mean change (AMΔ) ± SE in A1C from baseline to end point was −0.7
± 0.1% (P < 0.001) and −1.1 ± 0.1% (P < 0.001) in patients receiving 50 ... Cited by 147 - Related articles - BL Direct - All 10 versions
AJ Garber, A Schweizer, MA Baron, E … - Diabetes, Obesity and Metabolism, 2007 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 109 - Related articles - All 5 versions
FX Pi-Sunyer, A Schweizer, D Mills, S Dejager - Diabetes research and clinical practice, 2007 - Elsevier This 24-week, double-blind, randomized, multicenter, placebo-controlled,
parallel-group study performed in 354 drug-naïve patients with type 2 diabetes
(T2DM) assessed efficacy and tolerability of vildagliptin (50 mg qd, 50 mg ... Cited by 119 - Related articles - All 12 versions
S Dejager, S Razac, JE Foley, A Schweizer - Hormone and metabolic research, 2007 - cat.inist.fr This 24-week double-blind, randomized, multicenter, placebo-controlled,
parallel-group study was performed in 632 drug-naïve patients with type 2
diabetes to assess efficacy and tolerability of vildagliptin(50 mg qd, 50 ... Cited by 76 - Related articles - BL Direct - All 4 versions
J Rosenstock, MA Baron, R Camisasca, F … - Diabetes, Obesity and Metabolism, 2007 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 109 - Related articles - All 5 versions
- Free from Publisher J Rosenstock, MA Baron, S Dejager, D Mills, … - Diabetes Care, 2007 - ncbi.nlm.nih.gov OBJECTIVE: To compare the efficacy and tolerability of vildagliptin and
rosiglitazone during a 24-week treatment in drug-naïve patients with type 2
diabetes. RESEARCH DESIGN AND METHODS: This was a double-blind, randomized, ... Cited by 142 - Related articles - BL Direct - All 5 versions
V Fonseca, A Schweizer, D Albrecht, MA … - Diabetologia, 2007 - Springer Abstract Aims/hypothesis Type 2 diabetes is difficult to manage in patients with
a long history of disease requiring insulin therapy. Moreover, addition of most
currently available oral antidiabetic agents increases the risk of ... Cited by 104 - Related articles - BL Direct - All 4 versions
A Schweizer, A Couturier, JE Foley, S Dejager - Diabetic Medicine, 2007 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 89 - Related articles - BL Direct - All 4 versions
- ►januvia.se [PDF] - Free from Publisher B Charbonnel, A Karasik, J Liu, M Wu, G … - Diabetes Care, 2006 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—After a screening diet/exercise run-in period, a
metformin dose titration/stabilization period, and a 2-week, single-blind,
placebo run-in period, 701 patients, aged 19–78 years, with mild to ... Cited by 202 - Related articles - BL Direct - All 9 versions
D Holmes - Horm Metab Res, 2006 - rima.org The incretin hormones ± glucose−dependent insulinotropic poly− peptide
(GIP) and particularly glucagon−like peptide−1 (GLP−1) ± have been
reported to exert multiple metabolic effects that con− tribute to the ... Cited by 119 - Related articles - View as HTML - BL Direct - All 4 versions
